![[Feedback]](/icons/banner/feedbackACT.gif)
![[For Subscribers]](/icons/banner/subscriberACT.gif)
![[Archive]](/icons/banner/archiveACT.gif)
![[Search]](/icons/banner/searchACT.gif)
![[Contents]](/icons/banner/tocACT.gif)
Previous Article | Next Article 
Journal of Clinical Microbiology, April 2001, p. 1633-1637, Vol. 39, No. 4
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.4.1633-1637.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
B-Cell Epitope Mapping of the VapA Protein of
Rhodococcus equi: Implications for Early Detection of
R. equi Disease in Foals
Thiru
Vanniasinkam,1
Mary D.
Barton,1,2 and
Michael W.
Heuzenroeder2,*
School of Pharmacy and Medical Sciences,
University of South Australia,1 and
Infectious Diseases Laboratories, Institute of Medical and
Veterinary Science,2 Adelaide 5000, Australia
Received 9 October 2000/Returned for modification 19 December
2000/Accepted 29 January 2001
 |
ABSTRACT |
Linear B-cell epitopes of the Rhodococcus equi
virulence-associated protein (VapA) were mapped using a synthetic
peptide bank in this study. The peptides were screened in an
enzyme-linked immunosorbent assay (ELISA) with a total of 70 sera from
foals with current R. equi disease (51 sera), as well as
from foals that had either recovered from R. equi infection
10 months previously (3 sera) or that had no known history of R. equi disease (16 sera). An epitope with the sequence
NLQKDEPNGRA was identified and was universally recognized by
all 51 sera from foals with R. equi disease and was not
recognized by any of the other sera. There was poor reactivity between
all sera and peptides relating to other areas of the VapA protein. It
is proposed that an ELISA based upon a defined peptide epitope may be
used in an improved serological diagnostic test for R. equi
infection in foals.
| |
TEXT |
Rhodococcus equi is a
facultatively aerobic, gram-positive bacterium considered to be a soil
saprophyte (3). R. equi is a significant
pathogen in foals, causing a pyogranulomatous pneumonia which is
sometimes accompanied by extrapulmonary manifestations such as
bacteremia, lymphadenitis, and enteritis (2, 16). R. equi is also known to sometimes cause severe pulmonary and disseminated disease in immunocompromised humans, particularly in AIDS
patients (4).
Currently, an important virulence-associated factor identified in
R. equi disease in foals is considered to be the
virulence-associated protein, VapA (10, 22). This protein
is 15 to 17 kDa and is encoded by a gene present on a large 85- to
90-kb plasmid. Previous studies have shown that the majority of
clinical R. equi isolates from foals, unlike environmental
isolates, typically contain this virulence plasmid (8,
20). Giguere et al. have shown that this plasmid plays a role in
the intracellular survival and replication of R. equi in
host macrophages and consequently is an important factor for the
development of R. equi disease in foals (5). Importantly, studies have shown that the detection of significant levels of antibody to semipurified VapA is a reasonable marker of
virulent R. equi infection in foals (14;
S. A. Hines and S. K. Hietala, Editorial, Equine Vet. J. 28:339-340, 1996).
The aim of this study was to identify linear B-cell epitopes of VapA by
screening a synthetic peptide library based upon this protein with sera
from R. equi infected foals in an enzyme-linked immunosorbent assay (ELISA). Similar studies have been carried out on
other antigens associated with bacterial pathogens with success
(12, 13).
Peptide assay.
Biotinylated peptides synthesized by Mimotopes,
Victoria, Australia, were used in all of the assays. The peptide bank
used in the initial screening of sera was designed based upon the
published sequence of VapA (GenBank accession no. D21236)
(18). A total of 50 overlapping peptides, each 11 amino
acid residues in length (offset by 3 residues at a time), were
synthesized beginning from the predicted signal peptide cleavage site
between amino acids 31 and 32 up to and including the C terminus.
A second set of peptides was used to further define the region between
peptides 11 and 14 (LQKDEPNGRASD) of the VapA protein. A
total of 19 peptides were designed based upon this region; 12 were
truncated peptides and contained single stepwise amino acid deletions
starting from either the N or the C terminus. Six peptides were
overlapping 6-mers and covered the sequence offset by one residue at a
time beginning at the N terminus. A final peptide KDEPNGR
was designed based upon the core sequence of the B-cell epitope
identified in assays using the previous 18 peptides.
A total of 70 foal sera, most of these from animals aged between 4 to
12 weeks, were used to screen the peptides. Fifty-one sera were from
foals with current R. equi disease (positive sera). Sixteen
sera were from foals with no known history of R. equi infection, and three sera were from foals that had recovered from R. equi infection 10 months previously (negative sera).
Thirty-nine of the positive sera and all negative sera were obtained
from studs in South Australia and New South Wales, Australia. The
remaining sera were obtained elsewhere (Table
1).
The ELISA using the biotinylated peptides was performed by the method
recommended by the manufacturer with the following modifications: Neutravidin (Pierce Chemical Company) at a concentration of 0.3 µg/well was used to coat the plates. Plates were blocked for 2 h
at 4°C. The conjugate diluent used contained 1% casein to decrease the nonspecific binding. The secondary antibody used was caprine anti-horse immunoglobulin G (Bethyl Laboratories). The whole-cell antigen was prepared with R. equi ATCC 33701 (known to
contain the VapA-encoding virulence plasmid) using a previously
described method (1). Briefly, bacteria cultured on plates
for 48 h were harvested, washed with physiological saline, and
fixed overnight in 1% formalin in saline. The following day the
bacteria were washed three times in saline, resuspended in bicarbonate
coating buffer, and used in the ELISA. The whole-cell preparation was not tested for the presence of VapA or any other specific antigens.
Tetramethyl benzidine was used as the chromogenic substrate in all
assays, and optical density (OD) values were read in an ELISA plate
reader at a wavelength of 450 nm (reference wavelength, 630 nm).
Interpretation of data.
In the initial assay using the 50 peptides in the overlapping bank of the entire VapA protein, a positive
result was assigned by using a cutoff value of twice the background OD.
The background OD was the mean of the lowest 50% of all OD values
obtained with that particular serum, and all OD readings that were
twice this value were considered positive. The background ranged from
0.04 to 0.3, indicating a high degree of variability in the reactivity of sera with the peptide bank.
In the assay to identify the most reactive peptides containing elements
of region LQKDEPNGRASD, the cutoff OD value for a positive
result was determined using the mean value of the lowest 25% of all OD
values obtained with that serum (range, 0.13 to 0.78) plus three times
their standard deviation. All OD readings above the cutoff point were
considered positive.
A positive result in the R. equi whole-cell ELISA was based
upon twice the background OD. The background OD (0.07 to 0.37) was the
OD value of the well containing all reagents and sera used in the
corresponding test assay without the whole-cell antigen preparation.
All OD values above the background OD were considered positive.
Screening of sera with peptide bank of VapA sequence.
The 51 positive sera screened against 50 peptides recognized an epitope
between amino acids 62 to 81 of the VapA sequence corresponding to
peptides 11 to 14 (OD values between 0.25 and 1.5). The amino acid
sequences of these peptides are TSLNLQKDEPN (peptide 11),
NLQKDEPNGRA (peptide 12), KDEPNGRASDT (peptide
13), and PNGRASDTAGQ (peptide 14). Peptide 12 was
universally recognized by all 51 sera associated with current R. equi infection. Forty-nine of these sera recognized at least two
peptides in this region, and two sera were positive with only peptide
12 (Table 1). Thirteen sera were positive with all four peptides, i.e.,
peptides 11 to 14. Four sera were positive with peptides 15 or 16 in
addition to reacting with at least one peptide in the region from
peptides 11 to 14 (Fig. 1).
View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Fifty-one positive sera used to screen the fifty
overlapping peptides derived from the mature form of VapA in an ELISA.
A positive result is considered to be at least twice the background OD
at 450 nm (background OD range, 0.04 to 0.3). Numbers above columns
indicate the actual number of sera reacting with a given peptide.
|
|
In addition, 11 of the positive sera also reacted positively with one
or two of the peptides from 41 to 43 (region between amino acids 152 and 168 of VapA). The sequence of this secondary epitope did not have
any similarity to the sequence encompassed by peptides 11 to 14. Ten of
these sera gave a positive result with peptide 41, which corresponded
to sequence YLNINFFDSSG (Fig. 1).
Apart from these peptides, six sera reacted positively with peptides
from other regions of VapA (data not shown) and generally had OD
readings ranging from 0.13 to 0.6; however, these readings were much
less than those obtained with peptides 11 to 14 (0.25 to 1.5).
All sera from animals with no known history of R. equi
infection gave a negative result with peptides 11 to 14.
These assays show that a major linear epitope of VapA lies in the
region between peptides 11 and 14 corresponding to amino acids 62 to 81 of the VapA precursor protein sequence. Based on the universal
reactivity of peptide NLQKDEPNGRA, it is likely that a
B-cell epitope is in this region of VapA.
The region between peptides 11 and 14 of VapA contains predominantly
hydrophilic residues, and analysis of the precursor VapA sequence using
the Hopp and Woods hydrophobicity algorithm indicated that the region
corresponding to peptides 11 to 14 was the most hydrophilic region of
the entire protein (11). Studies have shown VapA to be a
lipid-modified, hydrophobic, surface-expressed protein
(19). Therefore, it would be expected that the hydrophilic region of this protein would lie on the cell surface and consequently be more likely to interact with the host immune system. Interestingly, the minor epitope identified between peptides 41 and 43 was within the
hydrophobic region of the VapA protein. This may mean that occasionally
non-cell-surface-exposed regions of VapA do interact with the host
immune system, although to a much lesser extent than the major cell
surface domain of the protein.
Further definition of the B-cell epitope within NLQKDEPNGRASD.
The 51 positive sera were tested against the peptides
LQKDEP, QKDEPN, KDEPNG, DEPNGR, EPNGRA, PNGRAS, NGRASD,
LQKDEPNGRASD, LQKDEPNGRAS, LQKDEPNGRA, LQKDEPNGR, LQKDEPNG,
LQKDEPN, QKDEPNGRASD, KDEPNGRASD, DEPNGRASD, EPNGRASD,
and PNGRASD. All of these sera gave relatively high OD values (between
0.5 and 1.17) with peptides containing KDEPNGR as part of
their sequence. However, none of the peptides was universally
recognized by all of the positive sera tested, unlike peptide 12 from
the initial VapA peptide bank (Fig. 2).
View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
Further definition of the B-cell epitope within
LQKDEPNGRASD using peptides derived from that sequence.
Positive peptides were defined as having an OD of at least three times
the standard deviation above the lowest 25% of all OD values at a
450-nm wavelength (OD range, 0.13 to 0.78). Numbers above columns
indicate actual numbers of sera reacting with a given peptide. The
universally reactive peptide 12 (NLQKDEPNGRA) has been
included for comparison.
|
|
These results indicated that it was not possible to further define or
shorten the epitope NLQKDEPNGRA since shortening of the
peptide in this region resulted in decreased OD readings with some
sera. Similar results relating to studies on various non-R. equi antigens have been reported by some researchers (S. Rodda, personal communication) and may occur because some antibodies in a
particular serum react more avidly with certain amino acid residues
than with others within the epitope. This would mean that a shortened
peptide may only react with a proportion of VapA antibodies present in
a particular serum, resulting in a weak-positive or false-negative
reaction. Previous studies relating to the epitope mapping of
Mycoplasma bovis variable surface lipoproteins have shown
B-cell epitopes to be around three to seven amino acid residues long
(17). However, other studies have shown universally
reactive B-cell epitopes relating to bacterial antigens to be as long
as 13 or even 15 residues (6, 25), similar to the size of
the 11-mer epitope NLQKDEPNGRA described here.
Comparison of peptide-based ELISA with a whole-R.
equi-cell-based ELISA.
Thirteen positive sera in the peptide
assay were negative in an ELISA based upon whole R. equi
cells. These sera gave lower OD readings (0.25 to 0.7) compared with
the remainder of the positive sera (0.7 to 1.7) in the peptide assay.
This indicates that with weakly positive sera, the whole-cell assay was
not as sensitive as the peptide assay.
Importantly, 10 negative sera in the peptide-based assay were positive
with the whole-cell ELISA. These may be false-positive results due to
the whole-cell assay detecting the presence of antibodies to non-VapA
antigens, expressed by nonpathogenic environmental R. equi,
that the foals had been exposed to.
The results clearly indicate that the peptide-based ELISA is superior
to that based upon whole cells because of its greater sensitivity. In
addition, the whole-cell assay was more time-consuming and
labor-intensive to perform compared to the peptide-based test. The
peptide assay also has the advantage in that the target peptide antigen
can be more readily quality controlled and easily produced in contrast
to a whole-cell extract.
Significance of the linear B-cell epitope of VapA.
There have
been other ELISA techniques developed for R. equi serology
in the past; these have mainly been assays using antigens of unknown
identity from R. equi, including Tween 20 extracts of a
VapA-negative R. equi ATCC 6939 (7, 21) and
lyophilized supernatant antigens of various strains of R. equi (9). Consequently, these assays did not
specifically detect antibodies to VapA. Furthermore, earlier studies
have demonstrated the presence of antibody against presumably
nonpathogenic R. equi in healthy horses and foals. This
highlights the importance of detection of VapA-specific antibodies in
order to differentiate between a clinical R. equi infection and environmental exposure to nonvirulent R. equi
(9). A VapA-based ELISA developed previously was found to
be more useful with respect to specificity; however, it was not
suitable for use as a routine diagnostic test, since VapA protein
extraction was laborious and possibly contained other antigens in
addition to VapA (14). Therefore, an ELISA based on
universally reactive synthetic peptide epitopes of the VapA protein has
the potential to be used as an easy-to-perform and specific routine
diagnostic test.
Recently, Takai et al. described six other virulence-associated
proteins
VapC, VapD, VapE, VapF, VapG, and VapHencoded by genes on the 80- to 90-kb R. equi virulence plasmid
(24). In addition, VapB associated with intermediately
virulent R. equi on a second plasmid has also been described
(23). None of these proteins contained regions of
significant homology to the B-cell epitope identified in this study
(23, 24).
In conclusion, the B-cell epitope of VapA identified in this study may
be used in a convenient and reliable diagnostic test for R. equi disease. Previous studies in the murine model indicate that
VapA may be important in the immune response to R. equi
(15), it is therefore possible that the epitope identified
in this study may be used as a component of a vaccine for the
prevention of R. equi disease in foals, particularly as a
component in a multivalent combination vaccine.
| |
ACKNOWLEDGMENTS |
We thank the Rural Industries Research and Development Corporation
and the University of South Australia for funding this project.
We thank Institute of Medical and Veterinary Science for the use of
equipment and facilities. We are grateful to Campbell Baker, Angela
Begg, Shinji Takai, Barbara Byrne, Glenn Browning, Phil Houston, and
Anna Morton for kindly providing the sera used in this study and Stuart
Rodda of Mimotopes for helpful discussions.
| |
FOOTNOTES |
*
Corresponding author. Mailing Address: Infectious
Diseases Laboratories, Institute of Medical and Veterinary Science,
Adelaide 5000, Australia. Phone: (08) 8222-3275. Fax: (08) 8222-3543. E-mail: heuzenroeder{at}imvs.sa.gov.au.
| |
REFERENCES |
| 1.
|
Barka, N.,
J. P. Tomasi, and S. Stadtsbaeder.
1986.
ELISA using whole Legionella pneumophila cell as antigen. Comparison between monovalent and polyvalent antigens for the serodiagnosis of human legionellosis.
J. Immunol. Methods
93:77-81[CrossRef][Medline].
|
| 2.
|
Barton, M. D., and D. H. Embury.
1987.
Studies of the pathogenesis of Rhodococcus equi infection in foals.
Aust. Vet. J.
64:332-339[Medline].
|
| 3.
|
Barton, M. D., and K. L. Hughes.
1984.
Ecology of Rhodococcus equi.
Vet. Microbiol.
9:65-76[CrossRef][Medline].
|
| 4.
|
Capdevila, J. A.,
S. Bujan,
J. Gavalda,
A. Ferrer, and A. Pahissa.
1997.
Rhodococcus equi pneumonia in patients infected with the human immunodeficiency virus. Report of 2 cases and review of the literature.
Scand. J. Infect. Dis.
29:535-541[Medline].
|
| 5.
|
Giguere, S.,
M. K. Hondalus,
J. A. Yager,
P. Darrah,
D. M. Mosser, and J. F. Prescott.
1999.
Role of the 85-kilobase plasmid and plasmid-encoded virulence-associated protein A in intracellular survival and virulence of Rhodococcus equi.
Infect. Immun.
67:3548-3557[Abstract/Free Full Text].
|
| 6.
|
Harboe, M.,
A. S. Malin,
H. S. Dockrell,
H. G. Wiker,
G. Ulvund,
A. Holm,
M. C. Jorgensen, and P. Andersen.
1998.
B-cell epitopes and quantification of the ESAT-6 protein of Mycobacterium tuberculosis.
Infect. Immun.
66:717-723[Abstract/Free Full Text].
|
| 7.
|
Higuchi, T.,
S. Hashikura,
C. Gojo,
T. Inui,
S. Satoh,
M. Yoshida,
T. Ishiyama,
H. Yamada, and S. Takai.
1997.
Clinical evaluation of the serodiagnostic value of enzyme-linked immunosorbent assay for Rhodococcus equi infection in foals.
Equine Vet. J.
29:274-278[Medline].
|
| 8.
|
Higuchi, T.,
S. Hashikura,
S. Gojo,
S. Hagiwara,
T. Inui,
S. Satoh,
M. Yoshida,
M. Fujii,
D. Hidaka,
S. Tsubaki, and S. Takai.
1997.
Isolation of virulent Rhodococcus equi from transtracheal aspirates of foals serodiagnosed by enzyme-linked immunosorbent assay.
J. Vet. Med. Sci.
59:1097-1101[CrossRef][Medline].
|
| 9.
|
Hietala, S. K.,
A. A. Ardens, and A. Sansome.
1985.
Detection of Corynebacterium equi-specific antibody in horses by enzyme-linked immunosorbent assay.
Am. J. Vet. Res.
46:13-15[Medline].
|
| 10.
|
Hondalus, M. K., and D. M. Mosser.
1994.
Survival and replication of Rhodococcus equi in macrophages.
Infect. Immun.
62:4167-4175[Abstract/Free Full Text].
|
| 11.
|
Hopp, T. P., and K. R. Woods.
1981.
Prediction of protein antigenic determinants from amino acid sequences.
Proc. Natl. Acad. Sci. USA
78:3824-3828[Abstract/Free Full Text].
|
| 12.
|
Norton, R. E.,
M. Heuzenroeder, and P. A. Manning.
1996.
Antigenic epitope mapping of the M24 protein of Streptococcus pyogenes: implications for serodiagnosis of rheumatic fever.
FEMS Immunol. Med. Microbiol.
16:267-271[CrossRef][Medline].
|
| 13.
|
Panchanathan, V.,
B. R. Naidu,
S. Devi,
A. Di Pasquale,
T. Mason, and T. Pang.
1998.
Immunogenic epitopes of Salmonella typhi GroEL heat shock protein reactive with both monoclonal antibody and patients sera.
Immunol. Lett.
62:105-109[CrossRef][Medline].
|
| 14.
|
Prescott, J. F.,
A. S. Fernandez,
V. M. Nicholson,
M. C. Patterson,
J. Yager,
A. L. Viel, and G. Perkins.
1996.
Use of a virulence-associated protein based enzyme-linked immunosorbent assay for Rhodococcus equi serology in horses.
Equine Vet. J.
28:344-349[Medline].
|
| 15.
|
Prescott, J. F.,
M. C. Patterson,
V. M. Nicholson,
B. Morein, and J. A. Yager.
1997.
Assessment of the immunogenic potential of Rhodococcus equi virulence associated protein (VapA) in mice.
Vet. Microbiol.
56:213-225[CrossRef][Medline].
|
| 16.
|
Prescott, J. F., and A. M. Hoffman.
1993.
Rhodococcus equi.
Vet. Clin. N. Am. Equine Pract.
9:375-384[Medline].
|
| 17.
|
Sachse, K.,
J. H. Helbig,
I. Lysnyansky,
C. Grajetzki,
W. Muller,
E. Jacobs, and D. Yogev.
2000.
Epitope mapping of immunogenic and adhesive structures in repetitive domains of Mycoplasma bovis variable surface lipoproteins.
Infect. Immun.
68:680-687[Abstract/Free Full Text].
|
| 18.
|
Sekizaki, T.,
S. Takai,
Y. Egawa,
T. Ikeda,
H. Ito, and S. Tsubaki.
1995.
Sequence of the Rhodococcus equi gene encoding the virulence-associated 15-17-kDa antigens.
Gene
155:135-136[CrossRef][Medline].
|
| 19.
|
Tan, C.,
J. F. Prescott,
M. C. Patterson, and V. M. Nicholson.
1995.
Molecular characterization of a lipid-modified virulence-associated protein of Rhodococcus equi and its potential in protective immunity.
Can. J. Vet. Res.
59:51-59[Medline].
|
| 20.
|
Takai, S.
1997.
Epidemiology of Rhodococcus equi infections: a review.
Vet. Microbiol.
56:167-176[CrossRef][Medline].
|
| 21.
|
Takai, S.,
S. Kawazu, and S. Tsubaki.
1986.
Immunoglobulin and specific antibody responses to Rhodococcus (Corynebacterium) equi infection in foals as measured by enzyme-linked immunosorbent assay.
J. Clin. Microbiol.
23:943-947[Abstract/Free Full Text].
|
| 22.
|
Takai, S.,
K. Koike,
S. Ohbushi,
C. Izumi, and S. Tsubaki.
1991.
Identification of 15- to 17-kilodalton antigens associated with virulent Rhodococcus equi.
J. Clin. Microbiol.
29:439-443[Abstract/Free Full Text].
|
| 23.
|
Takai, S.,
T. Anzai,
Y. Fujita,
O. Akita,
M. Shoda,
S. Tsubaki, and R. Wada.
2000.
Pathogenicity of Rhodococcus equi expressing a virulence-associated 20-kDa protein (VapB) in foals.
Vet. Microbiol.
76:71-80[CrossRef][Medline].
|
| 24.
|
Takai, S.,
S. A. Hines,
T. Sekizaki,
V. M. Nicholson,
D. A. Alperin,
M. Osaki,
D. Takamatsu,
M. Nakamura,
K. Suzuki,
N. Ogino,
T. Kakuda,
H. Dan, and J. F. Prescott.
2000.
DNA sequence and comparison of virulence plasmids from Rhodococcus equi ATCC 33701 and 103.
Infect. Immun.
68:6840-6847[Abstract/Free Full Text].
|
| 25.
|
Yamaguchi, H.,
T. Osaki,
M. Kai,
H. Taguchi, and S. Kamiya.
2000.
Immune response against a cross-reactive epitope on the heat shock protein 60 homologue of Helicobacter pylori.
Infect. Immun.
68:3448-3454[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, April 2001, p. 1633-1637, Vol. 39, No. 4
0095-1137/01/$04.00+0 DOI: 10.1128/JCM.39.4.1633-1637.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Torres, D., Espino, A. M.
(2006). Mapping of B-Cell Epitopes on a Novel 11.5-Kilodalton Fasciola hepatica-Schistosoma mansoni Cross-Reactive Antigen Belonging to a Member of the F. hepatica Saposin-Like Protein Family.. Infect. Immun.
74: 4932-4938
[Abstract]
[Full Text]
Top
Abstract
Text
